Regression of poloxamer 407-induced atherosclerotic lesions in C57BL/6 mice using atorvastatin

Atherosclerosis

Volumn 149, Issue 2, 2000, Pages 303-313

  Johnston, Thomas P ^a   Baker, Jacqueline C ^a   Hall, Douglas ^a   Jamal, Syed ^a   Palmer, Warren K ^b   Emeson, Eugene E ^c  

^a PFIZER INC   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Atherosclerosis; Atorvastatin; Coronary artery disease; HMG CoA reductase; Hyperlipidemia; Nonionic surfactant; Poloxamer 407; Regression

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MESSENGER RNA; POLOXAMER;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL LIVER LEVEL; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; HISTOLOGY; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; LIVER TOXICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

ANALYSIS OF VARIANCE; ANIMALS; ANTICHOLESTEREMIC AGENTS; ARTERIOSCLEROSIS; CHOLESTEROL, DIETARY; CHOLESTEROL, LDL; CULTURE TECHNIQUES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEMALE; HEPTANOIC ACIDS; INJECTIONS, INTRAPERITONEAL; LIVER; MICE; MICE, INBRED C57BL; POLOXAMER; PYRROLES; REFERENCE VALUES; REMISSION INDUCTION; TRIGLYCERIDES;

EID: 0034099366     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(99)00339-1     Document Type: Article

References (36)

1. Wout Z., Pec E.A., Johnston T.P. Poloxamer 407-mediated changes in plasma cholesterol and triglycerides following intraperitoneal injections to rats. J. Parent. Sci. Technol. 46:1992;192-200.
2. Palmer W.K., Emeson E.E., Johnston T.P. Poloxamer 407-induced atherogenesis in the C57BL/6 mouse. Atherosclerosis. 136:1998;115-123.
3. Report of the National Cholesterol Education Program Expert Panel in detection, evaluation and treatment of high blood cholesterol in adults. Arch Intern Med. 148:1988;36-69.
4. Summary of the second report of the National Cholesterol Education Program (NCEP) (Adult Treatment Panel II). J. Am. Med. Assoc. 269:1993;3015-3023.
5. Prevention of coronary heart disease: scientific background and new clinical guidelines. Nutr. Metab. Cardiovasc Dis. 2:1992;113-156.
6. Illingworth D.R. New horizons in combination drug therapy for hypercholesterolemia. Cardiology. 76(Suppl 1):1989;83-100.
7. Hunninghake D.B. HMG-CoA reductase inhibitors. Curr. Opin. Lipidol. 3:1992;22-28.
8. Endo A. The discovery and development of HMG-CoA reductase inhibitors. J. Lipid Res. 33:1992;1569-1582.
9. Baumann K.L., Butler D.E., Deering C.F., Mennen K.E., Millar A., Nanninga T.N. et al. The convergent synthesis of CI-981, an optically active, highly potent, tissue selective inhibitor of HMG-CoA reductase. Tetrahedron Lett. 33:1992;2283-2284.
10. Krause B.R., Bousely R., Kieft K., Stanfield R., Newton R.S. CI-981 is superior to lovastatin for lowering plasma triglycerides in experimental animals. Atherosclerosis. 117:1995;237-244.
11. McGuire E., Bailey D., Dominick M., Morse C., Sigler R., Walsh K. et al. Subchronic evaluation of a liver selective HMG-CoA reductase inhibitor in rodents and dogs. Toxicologist. 11:1991;A151. , Abstract.
12. Johnston T.P., Palmer W.K. Mechanism of poloxamer 407-induced hypertriglyceridemia in the rat. Biochem. Pharmacol. 46:1993;1037-1042.
13. Porter J., Carter B., Johnston T.P., Palmer W.K. Effect of pravastatin on poloxamer 407-induced hyperlipidemia in rats. Pharmacotherapy. 15:1995;92-98.
14. Johnston T.P., Palmer W.K. The effect of pravastatin on hepatic 3-hydroxy-3-methylglutaryl CoA reductase obtained from poloxamer 407-induced hyperlipidemic rats. Pharmacotherapy. 17(2):1997;342-347.
15. Johnston T.P., Palmer W.K. Effect of poloxamer 407 on the activity of microsomal 3-hydroxy-3-methylglutaryl CoA reductase in rats. J. Cardiovasc. Pharmacol. 29:1997;580-585.
16. Nash V.L., Johnston T.P., Palmer W.K. Effects of nicotinic acid on poloxamer 407-induced hyperlipidemia. Pharmacotherapy. 16:1996;10-15.
17. . Palmer W.K., Emeson E.E., Johnston T.P. The poloxamer 407-induced hyperlipidemic atherogenic animal model. Med. Sci. Sports Exerc. 29:1997;1416-1421.
18. Johnston TP, Baker JC, Hall DD, Jamal S, Emeson EE, Palmer WK. Potential down-regulation of HMG-CoA reductase following chronic administration of P-407 in C57BL/6 mice, J. Cardiovasc. Pharmacol., 1999, (in press).
19. Schmolka I.R. Tarch T. Polymers for Controlled Drug Delivery. 1991;189-215 CRC Press, Boca Raton.
20. Paigen B., Plump A.S., Rubin E.M. The mouse as a model for human cardiovascular disease and hyperlipidemia. Curr. Opin. Lipidol. 5:1994;258-264.
21. Jokinen M., Clarkson T., Prichard R. Animal models in atherosclerosis research. Exp. Mol. Path. 42:1985;1-28.
22. Ishida B.Y., Paigen B. Lusis A., Sparkes B. Genetic Factors in Atherosclerosis: Approaches in model systems. 1989;189-222 Karger, Basel.
23. Paigen B., Ishida B.Y., Verstuyft J., Winters R.B., Albee D. Atherosclerosis susceptibility differences among progenitors of recombinant inbred strains of mice. Arteriosclerosis. 10:1990;316-323.
24. Bucolo G., David H. Quantitative determination of serum triglycerides by the use of enzymes. Clin. Chem. 19:1973;476-479.
25. Allain C.A., Poor L.S., Chan C.S., Richmond W., Fu P.C. Enzymatic determination of total serum cholesterol. Clin. Chem. 20:1974;470-476.
26. Emeson E.E., Shen M.L. Accelerated atherosclerosis in hyperlipidemic C57BL/5 mice treated with cyclosporin A. Am. J. Pathol. 142:1993;1906-1915.
27. Chomczynski P., Sacchi N. Single step method of RNA isolation by acid guanidinium thiocynate-phenol-chloroform extraction. Anal. Biochem. 162:1987;156-159.
28. Snedecor G.W., Cochran W.G. Snedecor G.W., Cochran W.G. Statistical Methods. 1980;215-233 Iowa State University Press, Ames, IA.
29. Bocan T.M.A., Mazur M.J., Mueller S.B., Brown E.Q., Sliskovic D.R., O'Brien P.M. et al. Antiatherosclerotic activity of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase in cholesterol-fed rabbits: a biochemical and morphological evaluation. Atherosclerosis. 111:1994;127-142.
30. Zhu B.Q., Sievers R.E., Sun Y.P., Isenberg W.M., Parmley W.W. Effect of lovastatin on suppression and regression of atherosclerosis in lipid-fed rabbits. J. Cardiovasc. Pharmacol. 19:1992;246-255.
31. Kobayashi M., Ishida F., Takahashi T., Taguchi K., Watanabe K., Ohmura I., Kamei T. Preventive effect of MK-733 (Simvastatin), an inhibitor of HMG-CoA reductase, on hypercholesterolemia and atherosclerosis induced by cholesterol feeding in rabbits. Jpn. J. Pharmacol. 49:1989;125-133.
32. Breslow J.L. Mouse models of atherosclerosis. Science. 272:1996;685-688.
33. Corsini A., Raiteri M., Soma M.R., Bernini F., Fumagalli R., Paoletti R. Pathogenesis of atherosclerosis and the role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Am. J. Cardiol. 76:1995;21A-28A.
34. Soma M.R., Donetti E., Parolini C., Mazzini G., Ferrari C., Fumagalli R., Paoletti R. HMG-CoA reductase inhibitors: In vivo effects on carotid intimal thickening in normocholesterolemic rabbits. Arterioscler. Thromb. 13:1993;571-578.
35. Salonen R., Nyyssönen K., Porkkala-Sarataho E., Salonen J.T. The Kuopio Atherosclerosis Prevention Study (KAPS): effect of pravastatin treatment on lipids, oxidation resistance of lipoproteins, and atherosclerotic progression. Am. J. Cardiol. 76:1995;34C-39C.
36. Downs J.R., Clearfield M., Weis S., Whitney E., Shapiro D.R., Beere P.A. et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. J.Am. Med. Assoc. 279:1998;1615-1622.